Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

October 25, 2018

Study Completion Date

October 25, 2018

Conditions
Malaria
Interventions
BIOLOGICAL

PfSPZ-GA1 Vaccine

Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54

BIOLOGICAL

PfSPZ Vaccine

Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54

OTHER

Normal Saline

0.9% sodium chloride

BIOLOGICAL

Mosquito-bite CHMI

Bites of 5 infected mosquitoes of NF54 strain

Trial Locations (2)

2333 ZA

Leiden University Medical Center, Albinusdreef 2, Leiden

6525 GA

Radboud University Medical Center, Geert Grooteplein 28, Nijmegen

All Listed Sponsors
collaborator

Radboud University Medical Center

OTHER

collaborator

Leiden University Medical Center

OTHER

lead

Sanaria Inc.

INDUSTRY

NCT03163121 - Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers | Biotech Hunter | Biotech Hunter